Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan

Thomson K, Nachlis H. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval. JAMA. 2020 Aug 3doi: 10.1001/jama.2020.16253. Epub ahead of print. PMID: 32870235. Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents., 105949 Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Jul 23:NEJMoa2019014. Geleris, 2020, Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med., 382, 2411, 10.1056/NEJMoa2012410 News release: WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. 2020 Jul 04; Available from: https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 World Health Organization. The cardiotoxicity of antimalarials: Malaria Policy Advisory Committee Meeting. Published March 24, 2017. https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf Ray, 2012, Azithromycin and the Risk of Cardiovascular Death, N Engl J Med., 366, 1881, 10.1056/NEJMoa1003833 Woosley R, Heise C, Romero K. QTdrugs List, AZCERT, Inc. Available from: https://www.crediblemeds.org/ Salvi, 2008, A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients, J Am Geriatr Soc., 56, 1926, 10.1111/j.1532-5415.2008.01935.x Borba, 2020, Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial, JAMA Netw Open., 3, e208857, 10.1001/jamanetworkopen.2020.8857 Hama, 2016, The mechanisms of delayed onset type adverse reactions to oseltamivir, Infect Dis (Lond)., 48, 651, 10.1080/23744235.2016.1189592 Mercuro NJ, Yen CF, Shim DJ et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1; Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631 Tett, 1989, Bioavailability of hydroxychloroquine tablets in healthy volunteers, Br J Clin Pharmacol., 27, 771, 10.1111/j.1365-2125.1989.tb03439.x Shi, 2020, Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol., 5, 802, 10.1001/jamacardio.2020.0950 Puntmann, 2020, Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19), JAMA Cardiol., 27, e203557 Rajpal, 2020, Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection, JAMA Cardiol., 11, e204916 Chorin, 2020, QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin, Heart Rhythm., 10.1016/j.hrthm.2020.05.014 Chen Dong, Li X, Song Qifa, Hu C, Su F, Dai J. Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19). Infectious Diseases (except HIV/AIDS); 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.27.20028530 Arshad, 2020, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis., 97, 396, 10.1016/j.ijid.2020.06.099